Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Brigitte C. Widemann(National Cancer Institute), John P. Perentesis(University of Southern California), Rashmi Chugh(University of Michigan), Brian Turpin(Cincinnati Children's Hospital Medical Center), Angela C. Hirbe(Washington University in St. Louis), Yao Lu(Cornell University), Denise K. Reinke(Sarcoma Alliance for Research through Collaboration), AeRang Kim(Children's National), Eva Dombi(National Institutes of Health), Joseph G. Pressey(Cincinnati Children's Hospital Medical Center), Lee J. Helman(American Osteopathic Association), Christian F. Meyer(Sidney Kimmel Comprehensive Cancer Center), Ndidi Onwudiwe(Sarcoma Alliance for Research through Collaboration), Mohammed Milhem(University of Iowa), Nalini Jayaprakash(National Cancer Institute), Scott H. Okuno(Mayo Clinic), Gregory M. Coté(Harvard University), Karen Cichowski(Brigham and Women's Hospital)
Cited by 74
Related Papers
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557